ANI PHARMACEUTICALS, INC Proceeds from Lines of Credit
ANI PHARMACEUTICALS, INC (ANIP) reported Proceeds from Lines of Credit of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2024-02-29
- ANI PHARMACEUTICALS, INC proceeds from lines of credit for the quarter ending 2021-12-31 was $262.03M.
- ANI PHARMACEUTICALS, INC proceeds from lines of credit for the quarter ending 2021-09-30 was $0.00.
- ANI PHARMACEUTICALS, INC proceeds from lines of credit for the quarter ending 2021-06-30 was $24.00M.
- ANI PHARMACEUTICALS, INC proceeds from lines of credit for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- ANI PHARMACEUTICALS, INC proceeds from lines of credit for fiscal 2023 was $0.00.
- ANI PHARMACEUTICALS, INC proceeds from lines of credit for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- ANI PHARMACEUTICALS, INC proceeds from lines of credit for fiscal 2021 was $286.03M.
- ANI PHARMACEUTICALS, INC proceeds from lines of credit for fiscal 2020 was $0.00.
| Period end | Proceeds from Lines of Credit 1 month | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month | Proceeds from Lines of Credit 12 month as first filed |
|---|---|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-29 | |||||
| 2022-12-31 | $0.00 10-K · filed 2024-02-29 | |||||
| 2021-12-31 | $262.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $262.03M derived: sum of 2 quarters · filed 2024-02-29 | $286.03M derived: sum of 3 quarters · filed 2024-02-29 | $286.03M 10-K · filed 2024-02-29 | $300.00M 10-K · filed 2022-03-15 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $24.00M derived: sum of 2 quarters · filed 2021-11-01 | $24.00M 10-Q · filed 2021-11-01 | $9.00M derived: sum of 4 quarters · filed 2022-03-15 | ||
| 2021-06-30 | $24.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $24.00M 10-Q · filed 2021-08-06 | $9.00M derived: sum of 3 quarters · filed 2022-03-15 | $9.00M derived: sum of 4 quarters · filed 2022-03-15 | ||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | -$15.00M derived: sum of 2 quarters · filed 2022-03-15 | -$15.00M derived: sum of 3 quarters · filed 2022-03-15 | -$15.00M derived: sum of 4 quarters · filed 2022-03-15 | ||
| 2020-12-31 | -$15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$15.00M derived: sum of 2 quarters · filed 2022-03-15 | -$15.00M derived: sum of 3 quarters · filed 2022-03-15 | $0.00 10-K · filed 2022-03-15 | $15.00M 10-K · filed 2021-03-11 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $0.00 derived: sum of 2 quarters · filed 2021-11-01 | $15.00M 10-Q · filed 2021-11-01 | $15.00M derived: sum of 4 quarters · filed 2022-03-15 | ||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $15.00M 10-Q · filed 2021-08-06 | $15.00M derived: sum of 3 quarters · filed 2022-03-15 | $15.00M derived: sum of 4 quarters · filed 2022-03-15 | ||
| 2020-03-31 | $15.00M 10-Q · filed 2021-05-07 | $15.00M derived: sum of 2 quarters · filed 2022-03-15 | $15.00M derived: sum of 3 quarters · filed 2022-03-15 | $15.00M derived: sum of 4 quarters · filed 2022-03-15 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $0.00 derived: sum of 3 quarters · filed 2022-03-15 | $0.00 10-K · filed 2022-03-15 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 4 quarters · filed 2021-03-11 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $0.00 derived: sum of 3 quarters · filed 2021-03-11 | $0.00 derived: sum of 4 quarters · filed 2021-03-11 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-07 | $0.00 derived: sum of 2 quarters · filed 2021-03-11 | $0.00 derived: sum of 3 quarters · filed 2021-03-11 | $0.00 derived: sum of 4 quarters · filed 2021-03-11 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $0.00 derived: sum of 2 quarters · filed 2021-03-11 | $0.00 derived: sum of 3 quarters · filed 2021-03-11 | $0.00 10-K · filed 2021-03-11 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $0.00 derived: sum of 2 quarters · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $0.00 10-Q · filed 2018-08-07 | ||||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-08 | |||||
| 2017-09-30 | -$5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$5.00M derived: sum of 2 quarters · filed 2018-11-06 | $25.00M 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $30.00M 10-Q · filed 2018-08-07 | ||||
| 2017-03-31 | $30.00M 10-Q · filed 2018-05-08 | |||||
| 2017-02-28 | $30.00M 10-K · filed 2018-02-27 | |||||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $0.00 derived: sum of 2 quarters · filed 2017-11-02 | $0.00 10-Q · filed 2017-11-02 | |||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $0.00 10-Q · filed 2017-08-03 | ||||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |